Table 1

Misregulated genes in benign and malignant prostate samples

AccessionMean avg differenceMean avg differenceMean fold differenceP
Genea
 cdk 10L3326471 ± 0b950 ± 519c13.4<0.001
 HepsinX07732186 ± 230b7915 ± 4939c42.5<0.001
 Serotonin receptor 2BX7730771 ± 0b322 ± 161c4.5<0.001
Gened
 Phosphoglucomutase 5L409331136 ± 373b109 ± 83c10.40.011
Descriptione
 HMG-CoA reductaseM1105880 ± 27f335 ± 73g4.20.021
 Rad50U6313982 ± 24f333 ± 36g4.10.003
Geneh
 TYRO3 protein tyrosine kinaseU18934952 ± 301f134 ± 57g7.1<0.001
 Diacylglycerol kinaseX625351294 ± 527f127 ± 97g10.2<0.001
 Pyridoxal kinaseU89606628 ± 487f71 ± 0g8.80.014
 Stabilin 1/KIAA0246D874331240 ± 506f98 ± 24g12.6<0.001
 Protein kinase C, β 1X071091125 ± 541f80 ± 16g14.1<0.001
 ButyrophilinU90552390 ± 196f71 ± 0g5.50.002
 Early growth response 3X63741596 ± 374f71 ± 0g8.00.005
 Early growth response 2J04076881 ± 615f101 ± 12g8.70.009
 G protein α 16M63904913 ± 752f71 ± 0g12.90.016
  • a Up-regulated in tumors relative to normal.

  • b Normal.

  • c Tumor.

  • d Down-regulated in tumors relative to normal.

  • e Up-regulated in metastases relative to primaries.

  • f Primaries.

  • g Mets.

  • h Down-regulated in metastases relative to primaries.